The European Equity Fund, Inc. Announces Portfolio Manager Changes
NEW YORK--(BUSINESS WIRE)--The European Equity Fund, Inc. (NYSE: EEA) (the 'Fund') announced today that Hansjoerg Pack will replace Juan Barriobero as the Fund's portfolio manager effective July 1, 2025. Effective July 1, 2025, Mr. Barriobero, who has served as the Fund's portfolio manager since 2020, will replace Frank Kuemmet as the Fund's deputy portfolio manager.
Mr. Pack joined DWS in 1997 and has extensive portfolio management experience, including multiple global equity strategies with significant exposure to European markets. He also has experience in managing funds with significant allocations to German small and mid-cap equity securities, including DWS Aktien Strategie Deutschland (with current net assets of over EUR 2 billion) from 2016 to the present. Mr. Pack received a BA in Business Administration from Sheffield Hallam University; a Master's Degree in Economics ("Diplom-Volkswirt") from University of Duisburg-Essen; and is a CEFA - Certified European Financial Analyst.
Important Information
The European Equity Fund, Inc. is diversified and primarily focuses its investments in equity securities of issuers domiciled in Europe, thereby increasing its vulnerability to developments in that region.
Investing in foreign securities, particularly of emerging markets, presents certain risks, such as currency fluctuations, and risks of currency and capital controls, political and economic changes, and market risks. Any fund that concentrates in a particular segment of the market or a particular geographical region will generally be more volatile than a fund that invests more broadly.
The shares of most closed-end funds, including the Fund, are not continuously offered. Once issued, shares of closed-end funds are bought and sold in the open market through a stock exchange. Shares of closed-end funds frequently trade at a discount to net asset value. The price of a fund's shares is determined by a number of factors, several of which are beyond the control of the fund. Therefore, a fund cannot predict whether its shares will trade at, below, or above net asset value.
War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises and related geopolitical events have led, and, in the future, may lead to significant disruptions in US and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the funds and their investments.
This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.
Past performance is no guarantee of future results.
NOT FDIC/ NCUA INSURED • MAY LOSE VALUE • NO BANK GUARANTEE
NOT A DEPOSIT • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY
DWS Distributors, Inc.
222 South Riverside Plaza
Chicago, IL 60606-5808
www.dws.com
Tel (800) 621-1148
© 2025 DWS Group GmbH & Co. KGaA. All rights reserved
The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas, Inc. and RREEF America L.L.C. which offer advisory services. (R-106206) (05/25)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)
Two-year agreement expands Meridianbet and Golden Matrix's (GMGI) sports sponsorship portfolio across regulated European markets Aquatic Sports Association of Malta VALLETTA, Malta, June 04, 2025 (GLOBE NEWSWIRE) -- Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta. Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations. 'Water polo and aquatic sports are a vital part of Malta's sporting culture,' said Stefan Pavlovic, Malta territory director at Meridianbet. 'This partnership reflects our continued commitment to supporting national sports ecosystems, building long-term brand visibility in regulated markets, and delivering value to fans, players, local institutions and shareholders.' The ASA partnership builds on Meridianbet's growing sponsorship portfolio across 25+ international jurisdictions, where it supports sports ranging from football, basketball and MMA to eSports and grassroots competitions. This announcement also aligns with Meridianbet's broader ESG strategy. In 2024 alone, the company conducted 293 community engagement initiatives, reaching over 18,000 direct and indirect beneficiaries through education, healthcare, sports, and advocacy programs. Key Highlights of the Deal: Meridianbet named exclusive betting partner of Malta's ASA (governing body for water polo, swimming, artistic swimming) Launch of the Meridianbet Super Cup Brand exposure via LED ads, digital platforms, and team apparel To learn more about Meridianbet's community impact programs, visit About Meridianbet Founded in 2001, Meridianbet Group is a well-established online sports betting and gaming group, licensed and currently operating in 18 jurisdictions across Europe, Africa, and South America. The Meridianbet Group's successful business model utilizes proprietary technology and scalable systems, allowing it to operate in multiple countries and currencies with an omni-channel approach to markets, including retail, desktop online, and mobile. The Company is part of the Golden Matrix Group (Nasdaq: GMGI). For more information, visit IR Presentation - YouTube - Twitter - Email: ir@ A photo accompanying this announcement is available at
Yahoo
8 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Hill
14 minutes ago
- The Hill
Israel signed a record $14 billion in defense deals last year despite Gaza war criticism
JERUSALEM (AP) — Israel signed defense contracts worth nearly $15 billion last year, surpassing its all-time record, the country's defense ministry said Wednesday, even as international outrage mounts over the war in Gaza. Over half the deals were with European countries. The contracts — a 13% increase from 2023, itself a record year — came as Israel faces growing international condemnation and isolation over the nearly 20-month war. Some of Israel's closest allies, including Canada and France, recently stepped up their censure of Israel's actions in Gaza, and the U.K. suspended free trade talks. Some critics of Israel's conduct in the Palestinian enclave have called for countries to suspend trade with it. Some countries have taken steps to suspend defense contracts with Israel. Spain on Tuesday said it had canceled a deal for anti-tank missile systems that were to be manufactured in Madrid by a subsidiary of an Israeli company. A breakdown of Israel's 2024 defense deals by region: — European countries: 54% — Asia-Pacific: 23% — Arab countries that have normalized ties with Israel under the Trump-brokered Abraham Accords: 12% — North America: 9% — Latin America: 1% — Africa: 1% Nearly half the deals were for missiles, rockets and air defense systems, Israel's defense ministry said. Others included the sale of vehicles and armored personnel carriers, satellite and space systems and intelligence and cyber systems, among others. More than half of the agreements were worth over $100 million each. Israeli Defense Minister Israel Katz said the record amount was a 'direct result' of Israel's battlefield achievements throughout the wars that have roiled the Middle East since Hamas' Oct. 7, 2023, attack, in which militants killed 1,200 people and took 251 hostages. 'The world sees Israeli strength and seeks to be a partner in it,' Katz said in a statement. The war in Gaza has left much of the territory in ruins from Israel's punishing air campaign. The fighting has killed more than 54,000 people, mostly women and children, according to Gaza's Health Ministry, which does not say how many of the dead were civilians or combatants. A nearly three-month blockade on aid into Gaza also strained ties with Israel's international allies. Israel began allowing limited aid into the territory last month.
